Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GW786034 (pazopanib) Clear all
Terminated Phase 1 Interventional

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

NCT01060514
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Metastatic Breast Cancer
Interventions
Pazopanib, Vinorelbine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

NCT01593748
View directory record Official record
Conditions
Sarcoma
Interventions
Gemcitabine and Pazopanib, Gemcitabine and Docetaxel
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

NCT00463320
View directory record Official record
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Results available

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

NCT01184326
View directory record Official record
Conditions
Solid Tumor, Kidney Cancer
Interventions
pazopanib, everolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

NCT00370513
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

NCT01532687
View directory record Official record
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
Interventions
Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pazopanib, Pazopanib Hydrochloride, Placebo Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 4, 2026, 2:18 AM EDT
Terminated Phase 1 Interventional

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

NCT01548144
View directory record Official record
Conditions
Advanced Cancers
Interventions
Crizotinib (Xalkori), Pazopanib, Pemetrexed
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 4, 2026, 2:18 AM EDT
Recruiting Phase 1 Interventional

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

NCT07444619
View directory record Official record
Conditions
Soft Tissue Sarcomas
Interventions
Pazopanib, Trabectedin, Ipilimumab, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

NCT01466972
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Pazopanib
Drug
Lead sponsor
Hope Rugo, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Results available

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

NCT00800345
View directory record Official record
Conditions
Gynecologic Tumors
Interventions
Oral Topotecan, Pazopanib
Drug
Lead sponsor
Vector Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

An Extension to Study MD7108240

NCT00733304
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Pazopanib for Neoadjuvant Breast Cancer

NCT00849472
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery, pazopanib monotherapy
Drug · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
137
States / cities
Decatur, Alabama • Huntsville, Alabama • Antioch, California + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

NCT00731211
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
17
States / cities
San Francisco, California • Fort Myers, Florida • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00866697
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
35
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

NCT01235962
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Cancer
Interventions
pazopanib, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
69
States / cities
Jonesboro, Arkansas • Antioch, California • Beverly Hills, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

NCT00753688
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
PAZOPANIB, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 4, 2026, 2:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

NCT03660930
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
Interventions
Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 4, 2026, 2:18 AM EDT
Terminated Phase 2 Interventional

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

NCT01759303
View directory record Official record
Conditions
Osteosarcoma, Metastatic Osteosarcoma
Interventions
pazopanib
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor
Interventions
Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

SAbR For Oligometastatic Renal Cell Carcinoma

NCT02956798
View directory record Official record
Conditions
Oligometastatic Renal Cell Carcinoma
Interventions
Stereotactic ablative body radiation (SABR)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 1 Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911
View directory record Official record
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
View directory record Official record
Conditions
Macular Degeneration
Interventions
GW786034, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 4, 2026, 2:18 AM EDT
No Longer Available No phase listed Expanded access

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

NCT02354612
View directory record Official record
Conditions
Solid Tumors
Interventions
TRC105, Bevacizumab, Axitinib, Pazopanib, Capecitabine
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 4, 2026, 2:18 AM EDT
Completed Phase 1Phase 2 Interventional

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

NCT01719302
View directory record Official record
Conditions
Stage III Adult Soft Tissue Sarcoma
Interventions
Gemcitabine, Docetaxel, Pazopanib
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 4, 2026, 2:18 AM EDT